Cardiology Today -- In today’s online issue of the New England Journal of Medicine, Taylor et al described the results of an elegant study on the effects of ezetimibe vs. extended-release niacin on measures of mean common carotid intimal media thickness. The HALTS trial included adults treated with statin therapy who had documented atherosclerotic vascular disease, diabetes, a high 10-year Framingham risk estimate or high coronary calcification score with baseline LDL <100 mg/dL and HDL <50 mg/dL (men) or <55 mg/dL (women).
